Is Now a Good Time to Buy the Dip in Eli Lilly Stock?

Motley Fool11-21 22:00

The pharmaceutical giant's third-quarter earnings missed the mark across the board. Announcements from Amazon and out of Washington, D.C. may also be playing a role. Lilly remains well-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2485418284?lang=en_US&edition=fundamental","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F798070%2Fgetty-investing-time-to-sell.jpg&op=resize&w=165&h=104","is_english":true,"pubTime":"2024-11-21 22:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485418284","market":"fut","top_or_hot":-1,"title":"Is Now a Good Time to Buy the Dip in Eli Lilly Stock?","media":"Motley Fool","content":"<div>\n<p>The pharmaceutical giant's third-quarter earnings missed the mark across the board.\n\n\n\n\n\n\n\nAnnouncements from Amazon and out of Washington, D.C. may also be playing a role.\n\n\n\n\n\n\n\nLilly remains well-...</p>\n\n<a href=\"https://www.fool.com/investing/2024/11/21/is-now-good-time-to-buy-the-dip-in-eli-lilly-stock/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Now a Good Time to Buy the Dip in Eli Lilly Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Now a Good Time to Buy the Dip in Eli Lilly Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-21 22:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2024/11/21/is-now-good-time-to-buy-the-dip-in-eli-lilly-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The pharmaceutical giant's third-quarter earnings missed the mark across the board.\n\n\n\n\n\n\n\nAnnouncements from Amazon and out of Washington, D.C. may also be playing a role.\n\n\n\n\n\n\n\nLilly remains well-...</p>\n\n<a href=\"https://www.fool.com/investing/2024/11/21/is-now-good-time-to-buy-the-dip-in-eli-lilly-stock/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1066051811.HKD","symbol_name":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","start_time":0,"source_url":"https://www.fool.com/investing/2024/11/21/is-now-good-time-to-buy-the-dip-in-eli-lilly-stock/","article_id":"2485418284","we_media_id":null,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F798070%2Fgetty-investing-time-to-sell.jpg&op=resize&w=165&h=104"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485418284","pubTimestamp":1732197600,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Shares of Lilly are cratering, but investors may be surprised to learn what's influencing the volatility.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU2213496289.HKD":"ALLIANZ INCOME AND GROWTH \"AT\" (HKD) ACC","LU0079474960.USD":"联博美国增长基金A","LU0312595415.SGD":"Schroder ISF Global Climate Change Equity A Acc SGD","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU0048584097.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) INC","LU2430703178.SGD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (SGDHDG) INC","LLY":"礼来","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","SGXZ81514606.USD":"大华环球创新基金A Acc USD","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","IE00BKDWB100.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5H\" (SGDHDG) ACC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","BK4566":"资本集团","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","BK4527":"明星科技股","BK4579":"人工智能","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","BK4550":"红杉资本持仓","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","IE00BJJMRX11.SGD":"Janus Henderson Balanced A Acc SGD","AMZN":"亚马逊","IE00B19Z8W00.USD":"FTGF CLEARBRIDGE US LARGE CAP GROWTH \"A\" INC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU2054465674.USD":"UBS (LUX) KEY SELEC SICAV DIGITAL TRANSFORMATION T \"P\" (USD) ACC","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU0957791311.USD":"THREADNEEDLE (LUX) GLOBAL FOCUS \"ZU\" (USD) ACC","LU0289941410.SGD":"AB FCP I Dynamic Diversified AX SGD","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU0234572021.USD":"高盛美国核心股票组合Acc","LU2247934214.USD":"FIDELITY FUNDS SUSTAINABLE FUTURE CONNECTIVITY \"A\" (USD) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","IE0004091025.USD":"BNY MELLON GLOBAL OPPORTUNITIES \"B\" (USD) ACC","IE00BJTD4V19.USD":"NEUBERGER BERMAN US LONG SHORT EQUITY \"A1\" (USD) ACC"},"translate_title":"现在是逢低买入礼来公司股票的好时机吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1,"AMZN":0.9},"content_text":"The pharmaceutical giant's third-quarter earnings missed the mark across the board.\n\n\n\n\n\n\n\nAnnouncements from Amazon and out of Washington, D.C. may also be playing a role.\n\n\n\n\n\n\n\nLilly remains well-positioned to dominate the healthcare space in the long run.\n\nOwning shares of pharmaceutical giant Eli Lilly (LLY -1.54%) has generally been a great idea over the past year. Lilly's diabetes medication Mounjaro and its sibling treatment for chronic weight management Zepbound have evolved into blockbuster drugs in short order -- helping fuel Lilly stock to new all-time highs earlier this year.However, Lilly's shares (like pharmaceutical companies in general) tend to be quite volatile. As I write this, the stock has fallen by 12% just in the month of November. With the price now down 22% from intra-year highs, is now a good time to buy the dip in Eli Lilly stock?Let's take a look at what could be influencing the ongoing sell-off. From there, the case for or against investing in Lilly should become much clearer.Eli Lilly's earnings report was a letdownOn Oct. 30 Eli Lilly published financial results for the third quarter. To be blunt, its latest earnings were disappointing. Lilly missed Wall Street's expectations on both the top and bottom lines. To make matters worse, one of the primary culprits behind the swing and miss is the company's weight loss segment.If you've been following Lilly over the past year or so, you already know that balancing supply and demand for Mounjaro and Zepbound has been a daunting task. While Lilly has invested in manufacturing, these infrastructure investments will take time before the company can meet demand trends and scale its diabetes and obesity care medications consistently and seamlessly.Until that happens, Lilly is likely to continue experiencing outsized ebbs and flows in inventory levels for its medications. In turn, the pace at which it can accelerate revenue and profits will remain protracted.Image source: Getty Images.More headaches could be on the horizonIn the chart below, you can see Lilly's third-quarter earnings date annotated with the purple circle labeled \"E.\" It's pretty obvious that shares of Lilly have been cratering since the company reported earnings.However, around Nov. 6 it looks like the post-earnings sell-off reached a bottom, and the stock started to rebound. What's curious is that after remaining flat for a few days in early November, shares of Lilly have dropped again over just the last couple of days.LLY data by YChartsTwo factors could be taking a toll on Lilly's share price right now.The first is competition. Lilly's biggest competitor in the weight loss realm is Novo Nordisk -- the maker of Ozempic and Wegovy. Over the last few weeks, however, some other pharma players eyeing the weight loss market have been reporting progress updates on their clinical trials. Most notably, Viking Therapeutics is believed to be working on a quadruple-pathway obesity drug that could, if approved by the Food and Drug Administration (FDA), pose a serious headwind to incumbents such as Lilly.Then there's Amazon. On Nov. 14, the e-commerce and cloud computing juggernaut announced a host of updates for its telemedicine service, Amazon One Medical. The company has a long history of entering and disrupting new industries, and so it is natural that some investors might get spooked by Amazon's entrance into the healthcare arena. It's not time to panicAs I've often emphasized in my articles, panic-selling is rooted in emotion and rarely comes from a place of sound, reasonable judgment.As far as competition goes, Eli Lilly is one of the two current leaders in the weight loss space, along with Novo Nordisk. And while Viking and others are working on intriguing alternatives to Mounjaro, Zepbound, Ozempic, and Wegovy, I remain skeptical that any of these potential new medications will pose much of a threat.What's more, the total addressable market for these new weight loss treatments -- known as glucagon-like peptide-1 (GLP-1) agonists -- is expected to be $100 billion by 2030. In my eyes, the diabetes and obesity care markets are big enough, and therefore not a winner-take-all opportunity.On top of that, I see the announcement from Amazon as a benefit rather than a threat. Remember, Lilly already has a partnership with Amazon Pharmacy, which serves as an additional distribution channel for Lilly's weight loss medications. In addition, Amazon's announcement seems to be focused on lifestyle products for hair regrowth, eyelash growth, and more. I see this move as much more of a threat to Hims & Hers Health, which has been trying to encroach on Lilly's territory by selling compounded versions of mainstream weight loss treatments.While I can't say for certain that Amazon's moves or updates regarding Viking's GLP-1 pipeline really had anything to do with Lilly's sell-off over the last few days, the timing of these announcements and the sharp periods of selling do seem closely aligned:LLY data by YCharts.Despite all these unknowns, there are a couple of concrete catalysts for Lilly that seem to be overlooked right now. The company recently received FDA approval for an Alzheimer's drug and an eczema medication. Both of these markets represent over a $60 billion opportunity for Lilly in the long run.To me, buying Eli Lilly shares right now is a no-brainer. I think the recent sell-off is not warranted, and investors are missing the forest for the trees. The sell-off is a compelling opportunity to buy the dip in a company on the verge of revolutionizing multiple pockets of the healthcare realm.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485418284"}